One of the region's biggest drug makers wants Nasdaq Dubai to find a cure for its lack of liquidity.
While Hikma Pharmaceuticals says it has no immediate plans to delist from its home on Nasdaq Dubai,it has held talks with bourse officials about whether the UAE's exchanges will merge.
The drug manufacturer from Jordan is listed on both the London Stock Exchange (LSE) and Nasdaq Dubai since 2005.
No comments:
Post a Comment